DOCSLIB.ORG

GEMS REO ACUTE out of FORMULARY LIST Products Listed

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GEMS REO ACUTE out of FORMULARY LIST Products Listed GEMS REO ACUTE OUT OF FORMULARY LIST 1-Nov-13 Products listed on this formulary will attract a 30% co-payment if claimed on acute for the REO options. In conjunction with this, other rules may apply. ATC CLASS ATC Code ATC Description Nappi Drug Name Strength Drg Frm DRUGS FOR ACID RELATED DISORDERS A02 A02BC02 Pantoprazole 717376 ASPEN PANTOPRAZOLE 20MG ECT A02BC02 Pantoprazole 717377 ASPEN PANTOPRAZOLE 40MG ECT A02BC02 Pantoprazole 892291 CONTROLOC 20MG ECT A02BC02 Pantoprazole 812153 GASTRIWIN (WAS CONTROLOC) 40MG ECT A02BC02 Pantoprazole 717420 MYLAN PANTOPRAZOLE 20MG ECT A02BC02 Pantoprazole 717421 MYLAN PANTOPRAZOLE 40MG ECT A02BC02 Pantoprazole 708031 PANTOCID 40MG ECT A02BC02 Pantoprazole 881589 PANTOLOC 20MG ECT A02BC02 Pantoprazole 811793 PANTOLOC 40MG ECT A02BC02 Pantoprazole 714674 PENTOZ 20MG ECT A02BC02 Pantoprazole 714675 PENTOZ 40MG ECT A02BC02 Pantoprazole 718886 PENTOZ OTC 20MG TAB A02BC02 Pantoprazole 705368 TOPZOLE 20MG TAB A02BC02 Pantoprazole 705369 TOPZOLE 40MG TAB A02BC02 Pantoprazole 718142 TOPZOLE OTC 20MG ECT A02BC02 Pantoprazole 715312 CONORAN 20MG ECT A02BC02 Pantoprazole 715313 CONORAN 40MG ECT A02BC02 Pantoprazole 715610 PANTOCID 20MG ECT A02BC02 Pantoprazole 715306 PEPLOC 20MG ECT A02BC02 Pantoprazole 715307 PEPLOC 40MG ECT A02BC04 Rabeprazole 863106 PARIET 10MG TAB A02BC04 Rabeprazole 863114 PARIET 20MG TAB A02BC04 Rabeprazole 718384 RABEMED 10MG TAB A02BC04 Rabeprazole 718385 RABEMED 20MG TAB A02BC05 Esomeprazole 897132 NEXIAM 20MG TAB A02BC05 Esomeprazole 897125 NEXIAM 40MG TAB A02BC05 Esomeprazole 718879 NEXMEZOL 20MG TAB A02BC05 Esomeprazole 718880 NEXMEZOL 40MG TAB A02BX13 Alginic acid 711145 GAVISCON ADVANCE 10ML SAC A02BX13 Alginic acid 711031 GAVISCON ADVANCE PEPPERMINT SUS A02BX13 Alginic acid 862282 GAVISCON ADVANCE 500ML/5ML SUS A02BX99 Alginic acid and Combinations 715428 GAVISCON PLUS SUS LAXATIVES A06 A06AB04 Phenolphthalein 758345 PURITONE NO 1 250MG TAB A06AB04 Phenolphthalein 865370 SURGE LAXATIVE GRANULES 10G SAC DIGESTIVES, INCLUDING ENZYMES A09 A09AA Enzyme preparations 711079 LACTAZE EXTRA STRENGTH TAB A09AA02 Multienzymes (lipase protease etc.) 752479 PANKREOFLAT 170MG TAB DRUGS USED IN DIABETES A10 A10BB02 Chlorpropamide 719412 DIABINESE 250MG TAB A10BB02 Chlorpropamide 719439 DIABITEX 250MG TAB A10BB02 Chlorpropamide 714062 HYPOMIDE 250MG TAB A10BB07 Glipizide 743666 MINIDIAB 5MG TAB A10BB12 Glimepiride 716716 ACCORD GLIMEPIRIDE 4MG TAB A10BB12 Glimepiride 704895 ADCO-GLIMEPIRIDE 4MG TAB A10BB12 Glimepiride 831573 AMARYL 4MG TAB A10BB12 Glimepiride 711377 AMARYL 3MG TAB A10BB12 Glimepiride 714856 ASPEN GLIMEPIRIDE 4MG TAB A10BB12 Glimepiride 708007 DIAGLIM 4MG TAB A10BB12 Glimepiride 710209 EUGLIM 4MG TAB A10BB12 Glimepiride 704364 GLAMARYL 4MG 4MG TAB A10BB12 Glimepiride 707390 GLIMEHEXAL 4MG TAB A10BB12 Glimepiride 709986 MYLAN-GLIMEPIRIDE 4MG TAB A10BB12 Glimepiride 704675 SANDOZ GLIMEPIRIDE 4MG TAB A10BB12 Glimepiride 710906 SULPHONUR 4MG TAB A10BB12 Glimepiride 711910 ZYDUS-GLIMEPIRIDE 4MG TAB A10BF01 Acarbose 808164 GLUCOBAY 100MG TAB A10BF01 Acarbose 808156 GLUCOBAY 50MG TAB ANTITHROMBOTIC AGENTS B01 B01AC07 Dipyridamole 720526 PLATO 100MG TAB B01AC07 Dipyridamole 755656 PLATO 25MG TAB ANTIANEMIC PREPARATIONS B03 B03AB04 Iron and folic acid 710642 FEROFOL CAP B03AD Iron in combination with folic acid 866628 CHELA-FER 15MG/5ML SYR B03AD01 Ferrous amino acid complex 852279 CHELA-FER 15MG TAB B03AD01 Ferrous amino acid complex 703117 CHELA-FER 30MG TAB B03AD Iron in combination with folic acid 714891 FERRAMINO TAB B03AD Iron in combination with folic acid 714892 FERRAMINO FORTE TAB B03AD02 Ferrous fumarate 708229 FOLIRON FEF CAP B03AE Iron in other combinations 715834 ASTYFER CAP B03AE Iron in other combinations 715835 ASTYFER LIQ B03AE01 Iron vitamin B12 and folic acid 711147 CHELIRON FORTE TAB B03AE01 Iron vitamin B12 and folic acid 711148 CHELIRON TAB B03AE01 Iron vitamin B12 and folic acid 718728 CHELIRON SYRUP SYR B03AE01 Iron, vitamin B12 and folic acid 713274 FEROFOL SYR B03AE01 Iron vitamin B12 and folic acid 876917 FERROUS FORTE CHELATED IRON TAB B03AE01 Iron vitamin B12 and folic acid 893031 FERROUS FORTE CHELATED IRON SYR B03AE02 Iron multivitamins and folic acid 877917 FERROUS FORTE CHELATED IRON TAB B03AE10 Various combinations 710212 HAEMOFER JNR CAP B03AE10 Various combinations 710213 HAEMOFER CAP B03AE10 Various combinations 714956 HAEMOFER 10MG/5ML SYR B03BB01 Folic acid 702348 FOLIC ACID 5MG CAP B03BB01 Folic acid 874841 FOLIC ACID FORTE SR CAP CARDIAC THERAPY C01 C01DA02 Glyceryl trinitrate 787256 NITROLINGUAL AEROSOL SPRAY 0.4MG INH ANTIHYPERTENSIVES C02 C02AB01 Methyldopa 732079 HYPOTONE 500MG TAB DIURETICS C03 C03BA04 Chlortalidone 731919 HYGROTON 50MG TAB C03CA01 Furosemide 780839 LASIX 80MG TAB C03CA01 Furosemide 735973 LASIX RETARD 60MG CAP C03EA01 Hydrochlorothiazide and potassium-sparing agents 701815 ALDAZIDE 2.5MG/25MG TAB PERIPHERAL VASODILATORS C04 C04AD03 Pentoxifylline 703629 ASPEN PENTOXIFYLLINE 400MG SR 400MG TAB C04AD03 Pentoxifylline 709077 DYNA-PENTOXYFILLIN SR 400MG TAB C04AD03 Pentoxifylline 771961 TRENTAL 400 400MG TAB C04AX20 Buflomedil 738948 LOFTYL 150MG TAB VASOPROTECTIVES C05 C05CA01 Rutoside 752983 PAROVEN 250MG CAP BETA-BLOCKING AGENTS C07 C07AA05 Propranolol 732605 INDERAL LA 160MG CAP C07AA12 Nadolol 716189 CORGARD 80MG TAB C07AA12 Nadolol 716219 CORGARD-HS 40MG TAB C07AB02 Metoprolol 739251 LOPRESOR 100MG TAB C07AB02 Metoprolol 783323 LOPRESOR OROS 95MG TAB C07AB04 Acebutolol 705056 BUTOBLOC 400MG 400MG TAB C07AB04 Acebutolol 763020 SECTRAL 100MG CAP C07AB04 Acebutolol 763039 SECTRAL 200MG CAP C07AB04 Acebutolol 763047 SECTRAL 400MG TAB C07AG01 Labetalol 771627 TRANDATE 100MG TAB C07BA12 Nadolol and thiazides 716197 CORGARETIC-40 40MG TAB C07BA12 Nadolol and thiazides 716200 CORGARETIC-80 80MG TAB C07CB03 Atenolol and other diuretics 769592 TENORET 50 50MG/12.5MG TAB C07CB03 Atenolol and other diuretics 769568 TENORETIC 100MG/25MG TAB C07DA06 Timolol thiazides and other diuretics 744352 MODUCREN TAB C07DA06 Timolol thiazides and other diuretics 780472 SERVATRIN TAB CALCIUM CHANNEL BLOCKERS C08 C08CA02 Felodipine 821896 PLENDIL 2.5MG SRT C08CA03 Isradipine 782963 DYNACIRC 2.5MG TAB C08CA03 Isradipine 788325 DYNACIRC SRO 5MG CAP C08CA05 Nifedipine 796891 ADALAT RETARD 10MG TAB C08CA05 Nifedipine 783889 ADALAT RETARD 20MG TAB C08CA05 Nifedipine 793132 ADALAT XL 60MG SRT C08CA05 Nifedipine 711607 ADALAT XL 20MG TAB C08CA05 Nifedipine 711714 FEDALOC SR 60MG TAB C08CA05 Nifedipine 715001 MACOREL SR 60MG SRT C08CA05 Nifedipine 718085 BIO NIFEDIPINE XL 60MG SRT C08CA05 Nifedipine 715003 SPEC NIFEDIPINE SR 60MG SRT C08CA13 Lercanidipine 704035 ZANIDIP 10 10MG TAB C08CA13 Lercanidipine 708037 ZANIDIP 20MG TAB AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM C09 C09AA07 Benazepril 794066 CIBACE 20MG TAB C09BA04 Perindopril and diuretics 715650 ACESYL CO 0.625MG/2MG TAB C09BA04 Perindopril and diuretics 700512 PRETERAX TAB C09BA04 Perindopril and diuretics 713762 SPEC-PERINDOPRIL PLUS 0.625MG/2MG TAB C09BA09 Fosinopril and diuretics 836524 MONOZIDE 20MG/12.5MG TAB C09BB02 Enalapril and Lercanidipine 711445 ZANERIL 10MG/20MG 10MG/20MG TAB C09BB05 Ramipril and calcium channel blockers 862215 TRI-PLEN FORTE 5MG/5MG TAB C09BB10 Trandolapril and calcium channel blockers 836680 TARKA 180MG/2MG SRC C09CA02 Eprosartan 701855 TEVETEN 600 600MG TAB C09CA03 Valsartan 705488 DIOVAN 40 40MG TAB C09CA03 Valsartan 710051 DIOVAN 320MG TAB C09CA04 Irbesartan 837806 APROVEL 75MG TAB C09CA06 Candesartan 856118 ATACAND 16MG TAB C09CA06 Candesartan 856096 ATACAND 8MG TAB C09CA06 Candesartan 711287 ATACAND 32MG TAB C09CA06 Candesartan 719209 MYLACAND 8MG TAB C09CA06 Candesartan 719210 MYLACAND 16MG TAB C09DA02 Eprosartan and diuretics 708096 TEVETEN PLUS 600MG/12.5MG TAB C09DA03 Valsartan and diuretics 710048 CO-DIOVAN 320MG/12.5MG 320MG/12.5MG TAB C09DA03 Valsartan and diuretics 710050 CO-DIOVAN 320MG/25MG 320MG/25MG TAB C09DB01 Valsartan and amlodipine 719125 EXFORGE 5MG/320MG 5MG/320MG TAB C09DB01 Valsartan and amlodipine 719126 EXFORGE 10MG/320MG 10MG/320MG TAB C09DB01 Valsartan and amlodipine 719127 CO EXFORGE 10MG/320MG/25MG 10MG/320MG TAB C09DA06 Candesartan and diuretics 898635 ATACAND PLUS TAB C09DA06 Candesartan and diuretics 717580 ATACAND PLUS 32MG/12.5MG TAB C09DA06 Candesartan and diuretics 717723 ATACAND PLUS 32MG/25MG TAB LIPID MODIFYING AGENTS C10 C10AA04 Fluvastatin 813664 LESCOL 20MG CAP C10AA04 Fluvastatin 813672 LESCOL 40MG CAP C10AA04 Fluvastatin 700963 LESCOL XL 80MG ECT C10AA04 Fluvastatin 718208 VATICOL XL 80MG ECT C10AA07 Rosuvastatin 705989 CRESTOR 10MG 10MG TAB C10AA07 Rosuvastatin 705988 CRESTOR 20MG 20MG TAB C10AA07 Rosuvastatin 710892 CRESTOR 5MG TAB C10AA08 Rosuvastatin 705990 CRESTOR 40MG 40MG TAB C10AA07 Rosuvastatin 717520 ZUVAMOR 10MG TAB C10AA07 Rosuvastatin 717521 ZUVAMOR 20MG TAB C10AA08 Rosuvastatin 717522 ZUVAMOR 40MG TAB C10AA07 Rosuvastatin 719081 VUSOR 5MG TAB C10AA07 Rosuvastatin 719082 VUSOR 10MG TAB C10AA07 Rosuvastatin 719083 VUSOR 20MG TAB C10AA07 Rosuvastatin 719084 VUSOR 40MG TAB C10AA07 Rosuvastatin 719249 ROSVATOR 5MG TAB C10AA07 Rosuvastatin 719251 ROSVATOR 10MG TAB C10AA07 Rosuvastatin 719252 ROSVATOR 20MG TAB C10AA07 Rosuvastatin 719253 ROSVATOR 40MG TAB C10AD02 Nicotinic acid 899151 FLUSH FREE NIACIN TAB C10BX03 Atorvastatin and amlodipine 705835 CADUET 10MG/10MG 10MG/10MG TAB C10BX03 Atorvastatin and amlodipine 705836 CADUET 10MG/20MG 10MG/20MG TAB C10BX03 Atorvastatin and amlodipine 708835 CADUET 10MG/40MG 10MG/40MG TAB C10BX03 Atorvastatin and amlodipine 708837 CADUET 10MG/80MG 10MG/80MG
Load more

Recommended publications
  • Vasodilators for Primary Raynaud's Phenomenon
    Vasodilators for primary Raynaud's phenomenon Author Su, KYC, Sharma, M, Kim, HJ, Kaganov, E, Hughes, I, Abdeen, MH, Ng, JHK Published 2021 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD006687.pub4 Copyright Statement © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/405317 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Vasodilators for primary Raynaud's phenomenon (Review) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. www.cochranelibrary.com Vasodilators for primary Raynaud's phenomenon (Review) Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER........................................................................................................................................................................................................
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Identification of Potentially Inappropriate Medications with Risk
    Journal name: Clinical Interventions in Aging Article Designation: Original Research Year: 2019 Volume: 14 Clinical Interventions in Aging Dovepress Running head verso: Aguiar et al Running head recto: Aguiar et al open access to scientific and medical research DOI: 192252 Open Access Full Text Article ORIGINAL RESEARCH Identification of potentially inappropriate medications with risk of major adverse cardiac and cerebrovascular events among elderly patients in ambulatory setting and long-term care facilities This article was published in the following Dove Medical Press journal: Clinical Interventions in Aging João Pedro Aguiar1 Purpose: Cardiovascular diseases (CVDs) are extremely common among the elderly, but Luís Heitor Costa2 information on the use of potentially inappropriate medications (PIMs) with cardiovascular Filipa Alves da Costa3,4 risk is scarce. We aimed to determine the prevalence of PIMs with risk of cardiac and cere- Hubert GM Leufkens5 brovascular adverse events (CCVAEs), including major adverse cardiac and cerebrovascular Ana Paula Martins1 events (MACCE). Patients and methods: A cross-sectional study was performed using a convenience sample 1Research Institute for Medicines (iMED.ULisboa), Faculdade de from four long-term care facilities and one community pharmacy in Portugal. Patients were For personal use only. Farmácia, Universidade de Lisboa, included if they were aged 65 or older and presented at least one type of medication in their 2 Lisboa, Portugal; Serviço de medical and pharmacotherapeutic records from 2015 until December 2017. The main outcome Medicina Interna, Centro Hospitalar Psiquiátrico de Lisboa (CHPL), Lisboa, was defined as the presence of PIMs with risk of MACCE and was assessed by applying a Portugal; 3Centro de Investigação PIM-MACCE list that was developed from a previous study.
    [Show full text]
  • Pharmacology
    The Journalof VOLUME227 PHARMACOLOGY E3R 1983 AND EXPERIMENTAL THERAPEUTICS CONTENTS Prostaglandin H Synthase-Catalyzed Activation of Benzidine: A Model to Assess Pharmacologic Intervention of the Initiation of Chemical Carcinogenesis. Terry V. Zenser, Michael B. Mattammal, Ronald W. Wise, John R. Rice and Bernard B. Davis 545 Multiple Sites of Action of Ethanol on Adenylate Cyclase. Richard A. Rabin and Perry B. Molinoff 551 Blockade of the Behavioral Effects of Lysergic Acid Diethylamide, 2,5-Dimethoxy-4-Methylamphetamine, Downloaded from Quipazine and Lisuride by 5Hydroxytryptamine Antagonists. David J. Mokler, Randall L. Commissaris, Margaret R. Warner and Richard H. Rech 557 Discriminative Stimulus Properties of Nalorphine in the Rhesus Monkeys. Andrew H. Tang and R.obert A. Code 563 Interaction of a Radiolabeled Agonist with Cardiac Muscarinic Cholinergic Receptors. T. Kendall Harden, Rick B. Meeker and Michael W. Martin 570 Antiarrhythmic Effects of Ethmozin in Cardiac Purkinje Fibers: Suppression of Automaticity and Abolition of jpet.aspetjournals.org Triggering. Kenneth H. Dangman and Brian F. Hoffman 578 Psychopharmacological Effects of Melatonin in Mouse and Rat. David Sugden 587 Comparison ofDopamine Receptor Sites Labled by (3H1-S..Sulpride and I3HjSpiperone in Striatum. Nancy R. Zahniser and Margarita L. Dubocovich 592 Dissociation of Effects of Xanthine Analogs on Renal Prostaglandins and Renal Excretory Function in the Awake Rat. Philip G. Baer, Eyerce L. Armstrong and Lauren M. Cagen 600 at ASPET Journals on October 2, 2021 Binding Properties ofAlpha4 Adrenergic Receptors in Rat Cerebral Cortex: Similarity to Smooth Muscle. Kenneth P. Minneman 605 Effects of Buflomedil on the Responsiveness of Canine Vascular Smooth Muscle. P.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Säädk 415/2019
    SUOMEN SÄÄDÖSKOKOELMA MuuMnrovvvvLääkealanlääkeluettelosta asia turvallisuus- ja kehittämiskeskuksen päätös Julkaistu Helsingissä 29 päivänä maaliskuuta 2019 415/2019 Lääkealan turvallisuus- ja kehittämiskeskuksen päätös lääkeluettelosta Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääkelain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1§ Luettelon tarkoitus Tämä päätös sisältää luettelon Suomessa lääkkeellisessä käytössä olevista aineista ja rohdoksista. Lääkeluettelo laaditaan ottaen huomioon lääkelain 3 §:n ja 5 §:n säännökset. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ul- koisesti käytettynä parantaa, lievittää tai ehkäistä sairautta tai sen oireita ihmisessä tai eläi- messä. Lääkkeeksi katsotaan myös sisäisesti tai ulkoisesti käytettävä aine tai aineiden yh- distelmä, jota voidaan käyttää ihmisen tai eläimen elintoimintojen palauttamiseksi, kor- jaamiseksi tai muuttamiseksi farmakologisen, immunologisen tai metabolisen vaikutuk- sen avulla taikka terveydentilan tai sairauden syyn selvittämiseksi. Lääkeluettelo ei ole tyhjentävä. Tässä luettelossa mainitsemattomat aineet ja rohdokset, jotka täyttävät lääkelain lääkkeen määritelmän, ovat lääkkeitä. Lääkeluettelon vahvistamisen lisäksi Lääkealan turvallisuus- ja kehittämiskeskus päättää lääkelain 6 §:n nojalla tarvittaessa, onko ainetta tai valmistetta pidettävä lääkkeenä. Keskus päättää tapauskohtaisesti onko luettelossa olevaa ainetta sisältävää valmistetta pidettävä lääk- keenä
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-039747 Article Type: Original research Date Submitted by the 24-Apr-2020
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Microsoft Word
    AUTORISES INTERDITS AC. ACETYLSALICYLIQUE AC. MEFENAMIQUE AC. CLAVULANIQUE AC. NALIDIXIQUE AC. FUSIDIQUE AC. PIPEMIDIQUE AC. NIFLUMIQUE AC. PIROMIDIQUE AC. OXOLINIQUE ACITRETINE AC. TIAPROFENIQUE ADRAFINIL AC. TIENILIQUE ALCOOL AC. TRANEXAMIQUE ALIZAPRIDE ACAMPROSATE ALLOPURINOL ACEBUTOLOL ALMINOPROFENE ACETAZOLAMIDE ALPRAZOLAM ACICLOVIR ALVERINE ACTH AMBROXOL ADRENALINE AMIDOPYRINE ALFENTANIL AMINEPTINE ALFUZOSINE AMINOGLUTHETIMIDE ALIMEMAZINE AMIODARONE AMANTADINE AMISULPRIDE AMFEPRAMONE AMOBARBITAL AMIKACINE ANDROGENES AMILORIDE ARTICAINE AMITRIPTYLINE ASTEMIZOLE AMLODIPINE BACLOFENE AMOXAPINE BARBITURIQUES AMOXICILLINE BENFLUOREX AMPHOTERICINE B BENZBROMARONE APTOCAINE BENZYL THIOURACILE ATENOLOL BEPRIDIL ATRACURIUM BETAHISTINE ATROPINE BIPERIDENE AZATHIOPRINE BISOPROLOL BENAZEPRIL BROMOCRIPTINE BENSERAZIDE BUPIVACAINE (*) BETA-ALANINE BUSPIRONE BETAXOLOL CAPTOPRIL BEZAFIBRATE CARBAMAZEPINE BLEOMYCINE CEFACLOR BROMAZEPAM CEFPODOXIME BROMURE CEFUROXIME BUFLOMEDIL CHLORAMPHENICOL BUPRENORPHINE CHLORMEZANONE BUTACAINE CHLOROQUINE (*) BUTYLHYOSCINE CIBENZOLINE CARBIMAZOLE CICLETANINE CARPIPRAMINE CIPROFIBRATE CEFIXIME CLINDAMYCINE CEFOTAXIME CLOBAZAM CEFTAZIDIME CLOFIBRATE CEFTRIAXONE CLOMETHIAZOLE CELIPROLOL CLOMIFENE CERIVASTATINE CLONIDINE CETIRIZINE CLORAZEPATE CHLORAL HYDRATE CLOTIAZEPAM CHLORDIAZEPOXIDE CYCLOPHOSPHAM 1 DE CHLORPROMAZINE CYPROTERONE CICLOSPORINE DANAZOL CILAZAPRIL DAPSONE CIMETIDINE DENORAL® CIPROFLOXACINE DEXFENFLURAMINE CISAPRIDE DEXTROMORAMIDE CITALOPRAM DEXTROPROPOXYPHENE CLARITHROMYCINE DIAZEPAM CLIDINIUM DIHYDRALAZINE
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • Printable Version [PDF]
    A61K CPC COOPERATIVE PATENT CLASSIFICATION A HUMAN NECESSITIES HEALTH; AMUSEMENT A61 MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) NOTES 1. This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition: a. Drug or other biological compositions which are capable of: • preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides A01N 25/00 - A01N 65/00); • maintaining, increasing, decreasing, limiting, or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors, or the like (sex sterilants for invertebrates, e.g. insects, A01N; plant growth regulators A01N 25/00 - A01N 65/00); • diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or microorganisms C12Q; in vitro testing of biological material, e.g. blood, urine, G01N, e.g. G01N 33/48) b. Body treating compositions generally intended for deodorising, protecting, adorning or grooming the body, e.g. cosmetics, dentifrices, tooth filling materials.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]